Trial Profile
Phase I/II, Open Label, Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jan 2019
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Pacritinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 05 Sep 2017 Status changed from suspended to withdrawn prior to enrolment.
- 01 Sep 2016 Status changed from not yet recruiting to suspended as FDA has placed all trials involving Pacritinib on Full Clinical Hold .
- 17 Feb 2016 New trial record